On this page
Published: January 28, 2024 · Last reviewed: May 1, 2026
Key Takeaways
- Provisioning at scale needs unique device identity from manufacturing, not a shared default credential assigned at install.
- Certificate and key management across a multi-year fleet lifespan is an operational program, not a one-time PKI setup.
- Network segmentation is a joint responsibility: the manufacturer documents what the device needs, the hospital implements the VLAN and firewall rules.
- MDS2 is the disclosure mechanism hospitals use to evaluate fleet risk before and after purchase, and it needs to be accurate, not just complete.
- Patch delivery has to work across devices with intermittent connectivity and hospital-controlled maintenance windows.
- Shared clinical logins are a workflow reality, not a policy failure, and device design has to account for them rather than assume individual authentication will happen.
Part of our Hospital network, IoMT, and connected medical device security series. For the full overview, start with IEC 80001-1: Hospital Network Risk Management Explained.
Securing a hospital fleet of connected devices is a scale problem, not a single-device problem: provisioning thousands of units with unique identities, managing certificates and keys across their lifespan, and delivering patches without a truck roll to every hospital. The manufacturer owns device-resident security controls, certificate lifecycle, and patch packaging; the hospital owns network segmentation, physical access, and account administration. MDS2 disclosure and a documented end-of-support plan are what let both sides do their part.
A single connected infusion pump or vital-signs monitor is a small security problem. Three thousand of them, deployed across forty hospitals, provisioned over six years by different staff with different network configurations, is a different problem entirely. The devices that get compromised in real incidents are rarely the ones with a design flaw; they are the ones onboarded with a default certificate nobody rotated, or left on a flat network because segmentation was assumed rather than verified. Fleet-scale security fails at the seams between manufacturer and hospital responsibility, not usually inside either party's own controls.
Why This Matters
The FDA's final guidance Cybersecurity in Medical Devices: Quality Management System Considerations and Content of Premarket Submissions, issued February 3, 2026, continues the chain that began with the September 2023 premarket guidance and the June 2025 update, and it treats fleet-scale postmarket management as part of the total product lifecycle, not an afterthought. For connected accessory and monitoring devices sold in the hundreds or thousands of units, that means your submission has to describe how you provision, patch, and eventually decommission the fleet, not just how the individual device resists attack on a bench.
CISA's 2026 Minimum Elements for a Software Bill of Materials now supersede the NTIA's 2021 framework, and hospital procurement teams increasingly cross-reference your SBOM against MDS2 disclosures during purchasing review, not just at initial evaluation. AAMI SW96 (recognized as 13-131) and TIR97 (13-112) both expect postmarket controls scaled to actual deployment size. A device that is secure in isolation but has no realistic plan for certificate rotation or patch delivery across a real fleet does not meet that expectation, regardless of how clean its individual threat model looks.
How do you provision and onboard thousands of devices securely?
Secure provisioning means every device gets a unique cryptographic identity at manufacturing time, not a shared default that gets "personalized" during hospital install. Manufacturers who leave identity assignment to the field almost always end up with some devices still carrying the factory default, because on-site provisioning gets rushed and skipped under deployment pressure. Identity, including a device certificate or equivalent credential, needs to be injected during manufacturing and verifiable during onboarding, so a hospital can confirm the device is genuine before it ever joins the network.
| Provisioning stage | Manufacturer-side control | What fails without it |
|---|---|---|
| Manufacturing | Unique key or certificate injected per unit | Shared credentials across an entire product line |
| Shipping and staging | Signed configuration package, tamper-evident state | Devices arrive in an unverifiable trust state |
| Hospital onboarding | Automated registration against a defined identity | Manual entry errors, default credentials left active |
| Ongoing fleet inventory | Central device management console with real-time status | Hospital has no accurate count of what is actually deployed |
Zero-touch provisioning should be the default design goal for any device shipped in fleet quantities; every manual step in onboarding is a step that gets skipped somewhere in a large deployment.
How do you manage certificates and keys across a device fleet?
Certificate and key management has to be treated as an ongoing operational program with a defined rotation schedule, not a one-time PKI decision made at product launch. Devices that ship with certificates valid for the device's entire expected service life avoid one problem and create another: a compromised key stays valid for years with no path to revoke and reissue it. The realistic middle ground is certificates with a defined validity window and an automated renewal mechanism that does not require a service visit.
Manufacturers need a certificate authority strategy that survives their own organizational changes: what happens to device trust if the manufacturer changes its signing infrastructure, gets acquired, or discontinues a product line. A fleet with no answer to that question is a fleet that eventually loses the ability to trust its own devices.
Who owns network segmentation, the hospital or the manufacturer?
Network segmentation is implemented by the hospital, but the manufacturer owns telling the hospital exactly what the device needs to reach and nothing more. A device manufacturer cannot configure a hospital's VLANs or firewall rules, but a device that ships without a clear network requirements document forces IT staff to guess, and guessing usually produces an overly permissive rule set. The manufacturer's job is a documented, minimal set of required ports, protocols, and destinations that the hospital's network team can implement as a segmentation policy with confidence.
| Responsibility | Manufacturer owns | Hospital owns |
|---|---|---|
| Device network requirements | Documented minimal port/protocol list | Implementing the VLAN and firewall rules |
| Device-resident controls | Authentication, encryption, secure boot | Physical placement and access control |
| Credential lifecycle | Certificate issuance and renewal mechanism | Local account administration, badge access |
| Vulnerability disclosure | Coordinated disclosure process, patches | Applying patches within maintenance windows |
| Risk visibility | Accurate MDS2 and SBOM | Asset inventory and risk assessment across vendors |
The hospital's IT and biomed teams cannot segment what they do not know exists on the network, which is why an accurate device inventory feeding into the hospital's asset management is as important as the segmentation rule itself.
What does MDS2 actually need to say?
MDS2 is the disclosure document hospitals use to assess a device's risk profile during procurement and renewal, and it only works if the answers are specific rather than defensively vague. A form that answers "encryption used: yes" without specifying algorithm, key length, or scope gives a hospital security team nothing to evaluate. Hospitals increasingly cross-check MDS2 answers against the SBOM and against what the pentest report actually found, so inconsistency between those documents raises more questions than an honest gap would.
Our MDS2 and JSP2 post and role of MDS2 post go deeper on filling the form out in a way that actually holds up under a hospital security review.
How do you deliver patches across a fleet without disrupting care?
Patch delivery at fleet scale has to account for intermittent device connectivity and hospital-controlled maintenance windows, not assume every unit is reachable on demand. A device that requires a physical visit to apply a security patch will realistically go unpatched for a large share of the fleet, since biomed staff cannot service every unit on release day. The design goal is a signed, staged update mechanism that a device can pull and apply during a hospital-defined window, with rollback if the update fails.
See also: Embedded Cybersecurity Challenges MedTech, Radiology Information System: What It Is and How It Works, and NFC and Medical Device Cybersecurity.
Your postmarket plan needs a documented patch delivery mechanism, not just a patch development process; reviewers and hospital security teams both want to know how the fix actually reaches a device that may be offline for weeks.
Reporting matters as much as delivery. Hospitals need a way to see which devices in their fleet are on which firmware version, so a security team can answer "are we exposed to this CVE" without manually inventorying every unit.
How should end-of-support be communicated to hospitals?
End-of-support communication has to reach the hospital's security and procurement teams directly and early, not rely on a notice buried in a support portal. Hospitals plan capital budgets years in advance, and a device reaching end of support with no advance notice forces an unplanned replacement or, more commonly, continued use of an unsupported device with no compensating controls in place. Manufacturers should give hospitals a firm end-of-support date at launch when possible, and update it proactively rather than waiting for a customer to ask.
A realistic end-of-support communication includes what stops (security patches, vulnerability monitoring) and what a hospital should do in the interim, such as additional network isolation, since simply telling a hospital to "upgrade" ignores capital budget cycles that can run several years.
What do shared clinical accounts mean for device design?
Shared clinical logins are a workflow reality on hospital units, and device authentication design has to account for them rather than assume individual login will happen. A nurse moving between patients every few minutes will not log out and back in for each interaction, no matter what policy says, and a device that only supports a single shared credential loses all ability to attribute an action to a person. The practical fix is designing for fast, low-friction identity, such as badge tap or proximity authentication layered on top of a device-level credential, rather than insisting on password-based individual login that clinical workflow will simply route around.
Audit logging should be designed assuming shared accounts exist, capturing device and session context even when individual attribution is imperfect, rather than treating incomplete attribution as a reason to skip logging altogether.
How Blue Goat Cyber Approaches This
We evaluate fleet devices differently from single-unit devices, because the failure modes are different: provisioning gaps, certificate lifecycle blind spots, and patch delivery mechanisms that look fine in a lab and fail against real hospital connectivity. Our team tests the full deployment lifecycle, from manufacturing-time identity injection through onboarding, patch delivery, and decommissioning, not just the device's static attack surface.
For MDS2 and SBOM work, we help manufacturers write disclosures that will hold up when a hospital security team cross-references them against pentest findings, because inconsistency there damages trust faster than an honest limitation does. We also help manufacturers document the network requirements hospitals need to segment correctly, since a device that ships without that documentation puts the burden of guessing on hospital IT. If the FDA raises cybersecurity deficiencies after our submission work, we resolve them at no additional cost.
Frequently Asked Questions
CTA
If your fleet's provisioning, certificate management, or patch delivery plan only works on paper, a hospital security review or a real incident will find the gap before we do unless we find it first. Contact us to have your fleet security architecture and MDS2 disclosure reviewed together.
About the author
Christian Espinosa, MBA, CISSP · Founder & CEO, Blue Goat Cyber
U.S. Air Force Academy graduate and veteran with 30+ years in cybersecurity. Founded Alpine Security in 2014 (acquired 2020), then Blue Goat Cyber in 2022. Has supported 275+ FDA medical device submissions; no client has failed to clear due to cybersecurity. Author of three books including The Smartest Person in the Room. Ironman triathlete and mountaineer.
